Navigation Links
Central European Society for Anticancer Drug Research Announces Start of Enrollment in First Randomized Trial of Pharmacokinetic-Guided Dose Adjustment of Paclitaxel in Non-Small Cell Lung Cancer
Date:4/26/2011

VIENNA and BETHLEHEM, Pa., April 26, 2011 /PRNewswire/ -- In collaboration with Saladax Biomedical, Inc., the Central European Society for Anticancer Drug Research (CESAR) announced today that enrollment has begun in the CEPAC-TDM trial of paclitaxel therapeutic drug management (TDM) with subsequent pharmacokinetic-guided dose adjustment in patients being treated for advanced non-small cell lung cancer (NSCLC).  The study will determine if optimizing dosing of paclitaxel will reduce grade 4 neutropenia, without affecting progression-free survival and overall survival.  Saladax is developing a nanoparticle-based automated immunoassay to provide rapid, simple and cost-effective measurement of paclitaxel levels to allow timely personalized dose adjustment.

This multicenter randomized trial is planned to enroll 280 patients.  In the first phase of the study, eight study centers will participate in Germany and Switzerland, with the first three patients already enrolled in Lowenstein, Germany.  The study is sponsored by CESAR and supported by Saladax Biomedical.

The CEPAC-TDM study is the first large scale, randomized trial to evaluate the clinical utility of paclitaxel drug dose management and is the largest randomized trial of its type.  A dosing algorithm has been derived that uses 24-hour paclitaxel plasma concentration and clinical parameters, based on a large population model of paclitaxel. In addition to the clinical results, extensive data on health economic outcomes will be generated through the trial.

Markus Joerger, MD PhD, explains: "The CEPAC-TDM clinical trial has the potential to markedly improve patient quality of life through a reduction of febrile neutropenia and hospitalization, and debilitating neuropathy, as it tailors paclitaxel to the individual patient's drug metabolism."

Study details

The CEPAC-TDM study is a phase III open-label, randomized, parallel-group clinical trial compar
'/>"/>

SOURCE Saladax Biomedical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Symmetry Medical Centralizes Businesses Under CEO
2. Central Texas Hospital Selects eCareSoft EHR Technology
3. FDA Approves Gadavist for Central Nervous System Scans
4. U.S. FDA Approves Bayers Gadavistâ„¢ (Gadobutrol) Injection for MRI of the Central Nervous System
5. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
6. Reportlinker Adds The Outlook for Pharmaceuticals in Central Asia
7. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME)
8. Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME)
9. Cipher Pharmaceuticals Using MedAvante Centralized Ratings in Phase 3 Study
10. Rexahn to Use MedAvante Centralized Ratings in MDD Phase 2b Study
11. Wound Management Technologies Adds Panama to Growing List of Distribution Points in Central America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 As health officials across the ... select Meijer pharmacies in Michigan will ... eligible patients, enabling Meijer pharmacists to administer tests and, in ... by a physician participating in the study. The ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 2010 Renal Advantage and Liberty Dialysis, which last month ... dialysis services in the U.S., today announced that they have ... not disclosed – was completed on December 17, 2010.  The ... in 260 locations in 32 states. "The completion ...
... 22, 2010 Particle Sciences Inc. (PSI), a leading ... that, when coupled with an antigen, enhanced its immunogenicity, ... work is described in Vaccine , 2010 Dec. ... strong systemic and mucosal cellular and humoral immune responses ...
Cached Medicine Technology:Renal Advantage and Liberty Dialysis Deal Completed 2Renal Advantage and Liberty Dialysis Deal Completed 3Particle Sciences Develops Wax Nanoparticles that Enhance Immune Response to Antigens 2
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... team led by researchers at UC Davis has shown ... key role in cell division, also boosts the mitochondrial ... time the complex has been shown to perform both ... excellent target to control cellular energy production, potentially advancing ... online today in the journal Developmental Cell . ...
(Date:4/17/2014)... led by Cesar A. Arias, M.D., Ph.D., at The ... has identified a new superbug that caused a bloodstream ... the April 17 issue of The New England ... part of a class of highly-resistant bacteria known as ... a major cause of hospital and community-associated infections. The ...
(Date:4/17/2014)... uncommon these days to find a colored ribbon representing a ... cancer. But what color ribbon does one think of with ... color, for many suffering from the disease, black may be ... study consisting of lung cancer patients, primarily smokers between the ... light on the stigma often felt by these patients, the ...
(Date:4/17/2014)... alleviates muscle soreness after exercise, according to a ... at Chicago. , The study, reported online in ... Physical Medicine and Rehabilitation , also showed that ... not exercised, suggesting that massage has benefits for ... , Improved circulation and relief of muscle soreness ...
Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Massage therapy improves circulation, eases muscle soreness 2
... investments in nanoscale science and engineering will create revolutions ... treatment, and space travel. The hope is that many ... nanotechnology enabled products. While new technologies often do ... other social problems or create entirely new ones. The ...
... Reporter , THURSDAY, Nov. 18 (HealthDay News) -- Patients in ... because of cost than residents of other developed countries, a ... industrialized countries, the United States also has the highest out-of-pocket ... "The 2010 survey findings point to glaring gaps in ...
... into mice with metastatic melanoma has resulted in permanent ... cancer, according to an article to be published in ... Clinical Investigation . The online version is now available. ... modified lentivirus to introduce a potent anti-melanoma T cell ...
... nice extra, not a strategic imperative. But the data demonstrate ... L. Berry of Texas A&M University, Ann M. Mirabito of ... Texas MD Anderson Cancer Center. Their research shows that ... is impressive sometimes as high as six to one. ...
... WASHINGTON, Nov. 18, 2010 The latest episode in ... Global Challenges/Chemistry Solutions ," focuses on development and successful ... kills up to 98 percent of disease-causing bacteria in ... technology could aid many of the almost one billion ...
... Ill. -- Taking time off from certain osteoporosis drugs may ... at Loyola University Health System. Researchers found that bone density ... drug holiday from bisphosphonates, a popular class of osteoporosis drugs ... decay in the jaw bone. "These drugs are potentially ...
Cached Medicine News:Health News:Nanotechnology and equity issues explored in new book 2Health News:On Health Policies, U.S. Lags Other Nations: Survey 2Health News:On Health Policies, U.S. Lags Other Nations: Survey 3Health News:On Health Policies, U.S. Lags Other Nations: Survey 4Health News:Gene therapy for metastatic melanoma in mice produces complete remission 2Health News:Wellness programs provide high returns, research reveals 2Health News:Taking a break from osteoporosis drugs can protect bones 2
... 3 mirror lenses featuring ultra-clear Volk 3-Mirror ... 76°, 66° and 60°. The 3 ... well central and peripheral fundus viewing and ... angled to eliminate gaps in the visualized ...
... are a family of single-use direct view vitrectomy ... particular region of the retinal surface during eye ... 1 gram and is formed and polished to ... human cornea. Lenses come in boxes of 10 ...
... AFX Lens is a direct ... in an air-filled eye. In ... a primary air-fluid exchange vitrectomy ... sutureless design make it well ...
... Prism are designed for midperipherical ... for tractional retinal detachments (PDR, ... detachment. They can be used ... midperipheral laser applications. Direct image ...
Medicine Products: